156 related articles for article (PubMed ID: 36629993)
1. ASO Author Reflections: Preservation of the Thoracic Duct is Feasible for Esophageal Squamous Cell Carcinoma Patients Treated with Esophagectomy After Neoadjuvant Chemoradiotherapy.
Oshikiri T; Numasaki H; Oguma J; Toh Y; Watanabe M; Muto M; Kakeji Y; Doki Y
Ann Surg Oncol; 2023 May; 30(5):2699-2700. PubMed ID: 36629993
[No Abstract] [Full Text] [Related]
2. Is Thoracic Duct Resection Necessary for Esophageal Squamous Cell Carcinoma Patients Treated with Neoadjuvant Chemoradiotherapy? A Propensity-Matched Analysis Based on the Comprehensive Registry of Esophageal Cancer in Japan.
Oshikiri T; Numasaki H; Oguma J; Toh Y; Watanabe M; Muto M; Kakeji Y; Doki Y
Ann Surg Oncol; 2023 May; 30(5):2691-2698. PubMed ID: 36529778
[TBL] [Abstract][Full Text] [Related]
3. ASO Author Reflections: Exploring the Best Parameter for Lymph Node Assessment in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
Huang X; Tan L
Ann Surg Oncol; 2024 Feb; 31(2):899-900. PubMed ID: 38006528
[No Abstract] [Full Text] [Related]
4. Minimally Invasive Esophagectomy with Thoracic Duct Resection Post Neoadjuvant Chemoradiotherapy for Carcinoma Esophagus-Impact on Lymph Node Yield and Hemodynamic Parameters.
Anand S; Kalayarasan R; Chandrasekar S; Gnanasekaran S; Pottakkat B
J Gastrointest Cancer; 2019 Jun; 50(2):230-235. PubMed ID: 29344808
[TBL] [Abstract][Full Text] [Related]
5. ASO Author Reflections: Association Between Preoperative Coagulation Status and Prognosis in Patients Undergoing Subtotal Esophagectomy for Esophageal Squamous Cell Carcinoma After Neoadjuvant Treatment.
Sugiyama F; Kanda M; Kodera Y
Ann Surg Oncol; 2024 May; 31(5):3473-3474. PubMed ID: 38261127
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Biomarkers for Neoadjuvant Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma.
Okumura H; Noda M; Natsugoe S
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):715-716. PubMed ID: 30288651
[No Abstract] [Full Text] [Related]
7. ASO Author Reflections: Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from a Japanese Nationwide Study.
Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
Ann Surg Oncol; 2023 Sep; 30(9):5895-5896. PubMed ID: 37266806
[No Abstract] [Full Text] [Related]
8. ASO Author Reflections: Timing of Surgery and Chemoradiation for Esophageal Squamous Cell Carcinoma.
Wong LY; Berry MF
Ann Surg Oncol; 2023 Apr; 30(4):2224-2225. PubMed ID: 36607525
[No Abstract] [Full Text] [Related]
9. Significance of Thoracic Duct Resection During Esophagectomy for Esophageal Squamous Cell Carcinoma.
Kanaji S
Ann Surg Oncol; 2023 May; 30(5):2582-2583. PubMed ID: 36689032
[No Abstract] [Full Text] [Related]
10. ASO Author Reflections: Timing of Oesophagectomy After Neoadjuvant Chemoradiotherapy for Locally Advanced Oesophageal Cancer.
Xiao X; Cheng C; Cheng L; Yuan Y
Ann Surg Oncol; 2023 Feb; 30(2):897-898. PubMed ID: 36322273
[No Abstract] [Full Text] [Related]
11. ASO Author Reflections: Prognostic Stratification and the Value of Adjuvant Therapy in Thoracic Esophageal Squamous Cell Carcinoma Patients After Esophagectomy.
Deng W; Chen J; Xiao Z
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):802-803. PubMed ID: 31654164
[No Abstract] [Full Text] [Related]
12. ASO Author Reflections: A Novel, Sensitive, and Effective Index in Predicting Therapeutic Response of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Ann Surg Oncol; 2024 Jan; 31(1):241-242. PubMed ID: 37838649
[No Abstract] [Full Text] [Related]
13. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
[TBL] [Abstract][Full Text] [Related]
14. ASO Author Refections: Evaluation of Endoscopic Response After Neoadjuvant Chemotherapy Guides Distribution of Residual Diseases for Esophageal Squamous Cell Carcinoma.
Matsuda S; Kawakubo H; Tsuji T; Aoyama J; Hirata Y; Takemura R; Mayanagi S; Irino T; Fukuda K; Nakamura R; Takeuchi H; Kitagawa Y
Ann Surg Oncol; 2022 Apr; 29(4):2681-2682. PubMed ID: 34762213
[No Abstract] [Full Text] [Related]
15. ASO Author Reflections: Comparison of Aggressive Planned Salvage Surgery versus Neoadjuvant Chemoradiotherapy Plus Surgery for Borderline Resectable T4 Squamous Cell Carcinoma.
Shiraishi O
Ann Surg Oncol; 2021 Oct; 28(11):6376-6377. PubMed ID: 33830358
[No Abstract] [Full Text] [Related]
16. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients.
Chen CY; Li CC; Chien CR
World J Surg Oncol; 2018 Jul; 16(1):141. PubMed ID: 30007409
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
[TBL] [Abstract][Full Text] [Related]
20. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
